EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It

Magdalena K Zielińska, Magdalena Ciążyńska iD, Dorota Sulejczak iD, Piotr Rutkowski iD, Anna M Czarnecka iD

Biomolecules · 2025

DOI: 10.3390/biom15020269 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Magdalena K Zielińska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Immunotherapy, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carolina Zani Melanoma Foundation, Carolina Zani Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to anti-PD-1 therapy in melanoma remains a major obstacle in achieving effective and durable treatment outcomes, highlighting the need to understand and address the underlying mechanisms. The first key factor is innate anti-PD-1 resistance signature (IPRES), an expression of a group of genes associated with tumor plasticity and immune evasion. IPRES promotes epithelial-to-mesenchymal transition (EMT), increasing melanoma cells’ invasiveness and survival. Overexpressed AXL, TWIST2, and WNT5a induce phenotypic changes. The upregulation of pro-inflammatory cytokines frequently coincides with EMT-related changes, further promoting a resistant and aggressive tumor phenotype. Inflamed tumor microenvironment may also drive the expression of resistance. The complexity of immune resistance development suggests that combination therapies are necessary to overcome it. Furthermore, targeting epigenetic regulation and exploring novel approaches such as miR-146a modulation may provide new strategies to counter resistance in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDrug Resistance, NeoplasmImmunotherapyProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansTumor MicroenvironmentEpithelial-Mesenchymal TransitionAnimalsMicroRNAsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

anti-PD-1anti-PD-1 therapy resistancecheckpoint inhibitorsimmunotherapyinnate anti-PD-1 resistance signature (IPRES)melanomamelanoma immune evasionnivolumabpembrolizumabprimary resistancesecondary resistance

Substanzen

Programmed Cell Death 1 ReceptorMicroRNAsImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.
  • Chemotherapy Unit and Day Chemotherapy Ward, Specialised Oncology Hospital, 97-200 Tomaszów Mazowiecki, Poland.
  • Department of Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of Lodz, 91-347 Łódź, Poland.
  • Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.

ORCID-Profile: Magdalena Ciążyńska, Dorota Sulejczak, Piotr Rutkowski, Anna M Czarnecka

Förderung

  • Carolina Zani Melanoma Foundation
  • Carolina Zani Foundation

Zitieren

APA

Zielińska, M. K., Ciążyńska, M., Sulejczak, D., Rutkowski, P., & Czarnecka, A. M. (2025). Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It. Biomolecules. https://doi.org/10.3390/biom15020269

Vancouver

Zielińska MK, Ciążyńska M, Sulejczak D, Rutkowski P, Czarnecka AM. Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It. Biomolecules. 2025. doi:10.3390/biom15020269

BibTeX
@article{Zieliska2025,
  author = {Zielińska, Magdalena K and Ciążyńska, Magdalena and Sulejczak, Dorota and Rutkowski, Piotr and Czarnecka, Anna M},
  title = {Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15020269}
}
Kostenlos starten →